A randomised, double-blind, placebo-controlled trial of tropisetron in adult patients with attention-deficit/hyperactivity disorder (ADHD)
Latest Information Update: 12 May 2016
Price :
$35 *
At a glance
- Drugs Tropisetron (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Biomarker; Therapeutic Use
- 10 Dec 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 14 Dec 2010 New trial record